Biotech company located in the Barcelona Science Park (PCB), specializes in the development of first-in-class antibody-drug conjugates (ADCs) for advanced breast cancer and beyond.

The company has identified novel therapeutic targets involved in treatment resistance and the metastatic behaviour of tumor cells in patients with advanced cancer. Through the development of therapeutic biologics, Ona’s mission is to provide new and effective treatments for patients with no remaining alternatives. Founded in 2019, it was a spin-off from ICREA and IRB Barcelona.